Overview

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Status:
Completed
Trial end date:
2017-05-17
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Onyx Therapeutics, Inc.